Sparks - Oryzon Genomics

Oryzon Genomics has announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to the use of vafidemstat for treating non-aggressive symptoms of borderline personality disorder (BPD). The patent should provide protection to March 2043, including 1,095 days of patent term adjustment granted by the USPTO to compensate for delays during patent prosecution. We note that this does not include any potential patent term extensions, which could further extend the duration of coverage.

A ‘Decision to Grant’ has also recently been issued for a corresponding Canadian patent application in this patent family, covering the use of the drug candidate for the treatment of non-aggressive symptoms of BPD. In addition to the US and Canadian developments, corresponding patents have been granted or allowed in Australia, Europe, Japan, Malaysia, Mexico, Russia, Singapore and South Africa, with additional applications pending in other key regions. The non-US patents are expected to remain in place until at least 2040, excluding any potential patent term extensions or equivalent adjustments.